Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

City of Hope, Cellares collaborate to automate manufacturing of solid tumor CAR T-cell therapy

Cellares and City of Hope announced a collaboration to evaluate automated manufacturing of City of Hope’s investigational gene-modified CAR T-cell therapy targeting glioblastoma multiforme, an aggressive solid tumor brain cancer with limited treatment options.

January 16, 2026

Vol.52 No.02

Clinical Trials & Tribulations

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.

January 09, 2026

Vol.52 No.1

By Brendon M. Stiles

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

Clinical Roundup

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.

December 19, 2025

Vol.51 No.46

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

YOU MAY BE INTERESTED IN

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

City of Hope, Cellares collaborate to automate manufacturing of solid tumor CAR T-cell therapy

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Renew today!

Subscriber content

Never miss an issue!

Login